PHASE 2 STUDY OF TELAPREVIR ADMINISTERED Q8H OR Q12H WITH PEGINTERFERON-ALFA-2A OR -ALFA-2B AND RIBAVIRIN IN TREATMENT-NAiVE SUBJECTS WITH GENOTYPE 1. HEPATITIS C: WEEK 4 INTERIM RESULTS (vol 48, pg 4, 2008)

被引：0

作者：

Forns, X. ^{[1
]}

Marcellin, P. ^{[2
]}

Goeser, T. ^{[3
]}

Ferenci, P. ^{[4
]}

Nevens, F. ^{[5
]}

Carosi, G. ^{[6
]}

Drenth, J. P. ^{[7
]}

De Backer, K. ^{[8
]}

van Heeswijk, R. ^{[8
]}

Vangeneugden, T. J. ^{[8
]}

Picchio, G. ^{[9
]}

Beumont-Mauviel, M. ^{[8
]}

机构：

[1] Univ Barcelona, Liver Unit, Barcelona, Spain

[2] Hop Beaujon, Clichy, France

[3] Klinikum Univ Koln, Cologne, Germany

[4] Med Univ Vienna, Dept Internal Med 3, Vienna, Austria

[5] Univ Hosp Gasthuisberg, Dept Hepatol, B-3000 Louvain, Belgium

[6] Univ Brescia, Clin Infect & Trop Dis, Brescia, Italy

[7] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands

[8] Tibotec BVBA, Mechelen, Belgium

[9] Tibotec Inc, Yardley, PA USA

来源：

HEPATOLOGY | 2008年 / 48卷 / 06期

关键词：

D O I：

10.1002/hep.22702

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：2093 / 2093

页数：1

共 50 条

[31] Triple Therapy Under Real Life Conditions: Telaprevir (TVR) in Combination With Peginterferon-Alfa-2A Plus Ribavirin (P/R) in NaiVE Patients Infected With Chronic Hepatitis C, Genotype 1. The PAN Study
Moog, Gero
Mauss, Stefan
Hueppe, Dietrich
Spengler, Ulrich
Schott, Eckart
Eisenbach, Christoph
Schober, Andreas
Heyne, Renate
Jung, Maria-Christina
Teuber, Gerlinde
Doss, Margareta Frank
Roessle, Martin
Pape, Stefan
Schuchmann, Marcus
Alshuth, Ulrich
Buggisch, Peter
GASTROENTEROLOGY, 2013, 144 (05) : S983 - S983
[32] Daclatasvir, an NS5A Replication Complex Inhibitor, Combined With Peginterferon Alfa-2a and Ribavirin in Treatment-Naive HCV-Genotype 1 or 4 Subjects: Phase 2b COMMAND-1 SVR12 Results
Hezode, Christophe
Hirschfield, Gideon M.
Ghesquiere, Wayne
Sievert, William
Rodriguez-Torres, Maribel
Shafran, Stephen D.
Thuluvath, Paul J.
Tatum, Harvey A.
Waked, Imam
Esmat, Gamal E.
Lawitz, Eric
Rustgi, Vinod K.
Pol, Stanislas
Weis, Nina
Pockros, Paul
Bourliere, Marc
Serfaty, Lawrence
Vierling, John M.
Fried, Michael W.
Weiland, Ola
Brunetto, Maurizia R.
Everson, Gregory T.
Zeuzem, Stefan
Kwo, Paul Y.
Sulkowski, Mark S.
Brau, Norbert
Wind-Rotolo, Megan
Liu, Zhaohui
Hughes, Eric A.
Schnittman, Steven M.
Yin, Philip D.
HEPATOLOGY, 2012, 56 : 553A - 554A
[33] Clinical and economic implications of a 4-week viral negative response to peginterferon alfa-2b plus ribavirin for chronic hepatitis C and genotype 1 with low viral load
Wong, JB
Zeuzem, S
Manus, MP
Harvey, J
Albrecht, JK
HEPATOLOGY, 2005, 42 (04) : 679A - 679A
[34] ASUNAPREVIR WITH PEGINTERFERON-ALFA AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE-1 OR-4 CHRONIC HEPATITIS C: SVR24 RESULTS FROM A RANDOMIZED PHASE 2B STUDY (AI447016)
Bronowicki, J. -P.
Ratziu, V.
Gadano, A.
Thuluvath, P. J.
Bessone, F.
Martorell, C. T.
Pol, S.
Terg, R.
Younes, Z.
He, B.
Eley, T.
Cohen, D.
Mendez, P.
Hughes, E. A.
JOURNAL OF HEPATOLOGY, 2013, 58 : S571 - S572
[35] Interim results from HCV sprint-1: RVR/EVR from phase 2 study of boceprevir plus pegintrontm (peginterferon alfa-2b)/ribavirin in treatmentnaive subjects with genotype-1 CHC
Kwo, P.
Lawitz, E.
McCone, J.
Schiff, E.
Vierling, J.
Pound, D.
Davis, M.
Galati, J.
Gordon, S.
Ravendhran, N.
Rossaro, L.
Anderson, E.
Jacobson, I.
Rubin, R.
Mukhopadhyay, P.
Chaudhri, E.
Pedicone, L.
Albrecht, J.
JOURNAL OF HEPATOLOGY, 2008, 48 : S372 - S372
[36] TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA2A AND RIBAVIRIN FOR 24 OR 48 WEEKS IN TREATMENT-NAiVE GENOTYPE 1 HCV PATIENTS WHO ACHIEVED AN EXTENDED RAPID VIRAL RESPONSE: FINAL RESULTS OF PHASE 3 ILLUMINATE STUDY
Sherman, Kenneth E.
Flamm, Steven L.
Afdhal, Nezam H.
Nelson, David R.
Sulkowski, Mark S.
Everson, Gregory T.
Fried, Michael W.
Kleber, Kristin
Martins, Marie
Sankoh, Abdul J.
Kauffman, Robert S.
George, Shelley
Wright, Christopher I.
Poordad, Fred
HEPATOLOGY, 2010, 52 (04) : 401A - 402A
[37] Interim antiviral and safety data with albumin interferon alfa-2b combined with ribavirin in a phase 2b study conducted in a genotype 1, IFN-naive, chronic hepatitis C population
McHutchison, John
Zeuzem, Stefan
Benhamou, Yves
Shouval, Daniel
Bain, Vincent
Pianko, Steven
Flisiak, Robert
Grigorescu, Mircea
Rehak, Vratislav
Yoshida, Eric
Kaita, Kelly
Cronin, Patrick
Pulkstenis, Erik
Subramanian, Mani
HEPATOLOGY, 2006, 44 (04) : 614A - 614A
[38] A PHASE 2A STUDY OF BMS-791325, AN NS5B POLYMERASE INHIBITOR, WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION
Tatum, H.
Thuluvath, P.
Lawitz, E.
Martorell, C. T.
Demicco, M.
Cohen, S.
Rustgi, V.
Ravendhran, N.
Ghalib, R.
Hanson, J.
Zamparo, J.
Yang, R.
Hughes, E.
Cooney, E.
JOURNAL OF HEPATOLOGY, 2012, 56 : S460 - S460
[39] 36 VERSUS 48 WEEKS OF TREATMENT WITH PEGINTERFERON ALFA-2A PLUS RIBAVIRIN FOR GENOTYPE 1/4 PATIENTS WITH UNDETECTABLE HCV RNA AT WEEK 8: FINAL RESULTS OF A RANDOMIZED MULTICENTER STUDY
Lee, Samuel S.
Sherman, Morris
Ramji, Alnoor
Greenbloom, Susan
Elkashab, Magdy
Pluta, Henryk
Hilzenrat, Nir
Balshaw, Rob
Usaty, Christopher
Myers, Robert P.
HEPATOLOGY, 2010, 52 (04) : 359A - 359A
[40] Boceprevir Based Triple Therapy in Combination With Peginterferon-Alfa-2A Plus Ribavirin (P/R) Under Real Life Conditions in Treatment NaiVE Patients Infected With Chronic Hepatitis C, Genotype 1: An Interim Analysis At Week 12 After Start of Treatment
Moog, Gero
Mauss, Stefan
Hueppe, Dietrich
Spengler, Ulrich
Schott, Eckart
Eisenbach, Christoph
Schober, Andreas
Heyne, Renate
Jung, Maria-Christina
Teuber, Gerlinde
Doss, Margareta Frank
Roessle, Martin
Pape, Stefan
Schuchmann, Marcus
Alshuth, Ulrich
Buggisch, Peter
GASTROENTEROLOGY, 2013, 144 (05) : S982 - S983

← 1 2 3 4 5 →